Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$165.29

3.54 (2.19%)

, CWBHF

Charlotte's Web

$0.00

(0.00%)

12:50
04/06/19
04/06
12:50
04/06/19
12:50

Investors should not buy into craze for hemp stocks, Barron's says

Congress legalized hemp and its soothing extract cannabidiol, or CBD, and now the stock market cannot get enough of the stuff, Bill Alpert writes in this week's edition of Barron's. Cannabis producers like Canopy Growth (CGC), Aurora Cannabis (ACB) and Tilray (TLRY) quickly got into hemp and the stocks of companies that have long bet their business on CBD have doubled in recent months, including Charlotte's Web (CWBHF) and GW Pharmaceuticals (GWPH), he notes. Unfortunately, there are no bargains among hemp or marijuana stocks these days, the author contends. Reference Link

GWPH

GW Pharmaceuticals

$165.29

3.54 (2.19%)

CWBHF

Charlotte's Web

$0.00

(0.00%)

TLRY

Tilray

$59.56

-1.52 (-2.49%)

ACB

Aurora Cannabis

$9.16

0.225 (2.52%)

CGC

Canopy Growth

$43.27

0.03 (0.07%)

GWPH GW Pharmaceuticals
$165.29

3.54 (2.19%)

03/04/19
PIPR
03/04/19
NO CHANGE
PIPR
Piper Jaffray sees continued medical cannabis growth
Piper Jaffray analyst Michael Lavery writes that his discussions with a medical pain specialist in New York affirm his expectations of continued growth for medical cannabis, particularly as practitioners search for opioid alternatives. With over 30 U.S. states now in favor of medical use of marijuana, the analyst believes that the national prohibition will end in the next few years with the "STATES Act or federal legalization". Lavery is positive on Tilray (TLRY) and its partnership with Novartis (NVS) to develop and distribute medical cannabis products, keeping his Overweight rating and $90 price target on the shares. The analyst also calls GW Pharma (GWPH) a "trailblazer for developing cannabis-derived products for medical use", with its FDA-approved epidiolex cannabidiol product, keeping his Overweight rating and $195 price target on the stock. Lavery further maintains his Overweight rating and $60 price target on Canopy Growth (CGC) given its current valuation.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $185
PIPR
Overweight
GW Pharmaceuticals price target raised to $185 from $180 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for GW Pharmaceuticals to $185 saying the Epidiolex launch is off to a "very strong start" and still gaining momentum. Management commentary indicates the launch is "living up to the hype," Brill tells investors in a post-earnings research note. Further, she believes GW has the infrastructure in place to meet high demand. The analyst reiterates an Overweight rating on the shares.
02/26/19
PIPR
02/26/19
NO CHANGE
PIPR
GW metrics indicate 'hugely successful' Epidiolex launch, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says GW Pharmaceuticals' Epidiolex revenues of $4.7M for the first quarter of commercial launch beat her $3.7M and consensus $2.5M estimate. While these numbers "solidly beat expectations," they are still not truly representative of Epidiolex's launch trajectory, Brill tells investors in a post-earnings research note titled "Epidiolex Metrics Signify a Hugely Successful Launch." She notes that Q4 was a stub quarter, as Eepidiolex launched in early November, which included two holiday weeks and that refill rates were likely very low due to protracted initial turnaround times. The analyst expects to see "significant" revenue growth in the coming quarters. She has an Overweight rating on GW Pharmaceuticals, which is trading up 8.1%, or $12.41, to $165.30 following the earnings report.
02/22/19
GUGG
02/22/19
INITIATION
Target $178
GUGG
Buy
GW Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated GW Pharmaceuticals with a Buy rating and $178 price target, stating that the company's "state-of-the-art Cannabis-based platform" has the potential to deliver drugs for several neurological disorders and lead drug, Epidiolex, should have a successful launch.
CWBHF Charlotte's Web
$0.00

(0.00%)

03/07/19
ROTH
03/07/19
INITIATION
ROTH
Buy
Charlotte's Web initiated with a Buy at Roth Capital
Roth Capital analyst Scott Fortune started coverage of Charlotte's Web with a Buy rating and a C$26.50 price target. The analyst believes Charlotte's Web is a market leader in the fast-growing hemp extract cannabidiol market with high-quality supply, a recognized brand, and significant new retail verticals to begin selling into the mass-market. The 2018 Farm Bill federally legalizes hemp-derived CBD products and Fortune expects consumer acceptance, mass-market retailer adoption, supply advantages, and interest from CPG companies and Canadian LPs to drive future returns for shareholders.
TLRY Tilray
$59.56

-1.52 (-2.49%)

03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
03/19/19
PIPR
03/19/19
NO CHANGE
Target $90
PIPR
Overweight
Piper maintains Overweight rating, $90 target on Tilray after Q4 results
After Tilray reported a Q4 EBITDA loss of ($17.8M), Piper Jaffray analyst Michael Lavery says he does not expect positive earnings in near-term, as the company will remain in investment mode to drive growth. The Canadian market may become profitable as it ramps up, contends the analyst, but he does not expect positive total company EBITDA over the next five-to-seven quarters. However, Lavery expects strong industry growth long-term, and believes Tilray is well positioned to be one of several likely winners. He maintains an Overweight rating on the shares with a $90 price target.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/19
JEFF
03/08/19
INITIATION
Target $61
JEFF
Underperform
Tilray falls after Jefferies starts with Underperform rating, $61 target
Shares of Tilray (TLRY) are moving lower after Jefferies analyst Owen Bennett initiated coverage of the shares with an Underperform rating and $61 price target. Underperform is Jefferies' equivalent of a sell rating. Shares of Tilray are down 4%, or $2.97, to $66.75 in premarket trading. Bennett's 10-year discounted cash flow-driven valuation suggests the stock is "too expensive for its outlook." As a company wanting to be a global leader, the names that Tilray needs to be compared to are Canopy Growth (CGC) and Aurora Cannabis (ACB), Bennett tells investors in a research note. However, Tilray's Canada medical share is not in the top four and recent consumer feedback is "not inspiring," adds the analyst. Further, he believes the company's approach to recreational "does not appear as well thought through" and that its "optionality" in the U.S. is "less impressive." As such, Bennett struggles to justify Tilray's current valuation.
ACB Aurora Cannabis
$9.16

0.225 (2.52%)

03/13/19
03/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Carnival (CCL) upgraded to Buy from Neutral at Goldman Sachs analyst Stephen Grambling citing the company accelerating its net unit growth from 2.5% in the last 3 years to 5% over the next 3 years and also believes that concerns about net yields in Europe are overblown. 2. Sanderson Farms (SAFM) upgraded to Neutral from Underweight at JPMorgan with analyst Ken Goldman saying he now views the stock's upside/downside risk as balanced. 3. Axis Capital (AXS) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying Axis is positioned for strong underwriting improvement. 4. Broadridge (BR) upgraded to Outperform from Market Perform at Raymond James with analyst Patrick O'Shaughnessy saying he believes Broadridge's current valuation offers investors an attractive entry point into a differentiated, high barrier to entry business. 5. Aurora Cannabis (ACB) upgraded to Buy from Hold at GMP Securities with analyst Martin Landry saying new high profile strategic advisor Nelson Peltz could be "instrumental" in facilitating partnership talks with large consumer packaged goods companies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
MITR
03/13/19
UPGRADE
Target $15
MITR
Buy
Aurora Cannabis upgraded to Buy from Hold at GMP Securities
GMP Securities analyst Martin Landry upgraded Aurora Cannabis to Buy from Hold and raised his price target to $15 from $9.50. In a research note to investors, Landry says new high profile strategic advisor Nelson Peltz could be "instrumental" in facilitating partnership talks with large consumer packaged goods companies. Additionally, the analyst says its fully-licensed Bradford and Aurora Sky facilities should alleviate inventory concerns.
03/13/19
MITR
03/13/19
UPGRADE
MITR
Buy
Aurora Cannabis upgraded to Buy from Hold at GMP Securities
CGC Canopy Growth
$43.27

0.03 (0.07%)

04/04/19
JEFF
04/04/19
NO CHANGE
Target $255
JEFF
Buy
Jefferies views Constellation sale of wine brands favorably
Earnings dilution from a sale of wine brands, along with Canopy Growth (CGC) investment dilution in fiscal 2020 has been an overhang for Constellation Brands (STZ) in recent months, Jefferies analyst Kevin Grundy tells investors in a research note. The analyst says that despite negative earnings implications, he views Constellation's sale of value wine brands to E. & J. Gallo for $1.7B favorably as the "consideration appears reasonable for a declining wine business." Further, and importantly, the sale shifts focus to the company's higher "growth/margin/return" portfolio of assets, namely beer, contends Grundy. Constellation remains the analyst's top pick with a Buy rating and $255 price target.
04/02/19
GHSC
04/02/19
NO CHANGE
GHSC
Neutral
Canopy estimates lowered at Seaport Global following peer reports
Seaport Global analyst Brett Hundley lowered his near-term revenue and EBITDA estimates for Canopy Growth (CGC) after recent earnings reports from HEXO Corp. (HEXO) and Cronos (CRON) highlighted broader Canadian industry inventory build and "marketplace inefficiency." He thinks it is prudent to be somewhat conservative related to store rollouts this spring along with the development of the nationwide edibles/beverages market later this year. Hundley keeps a Neutral rating on Canopy shares.
04/05/19
MSCO
04/05/19
NO CHANGE
Target $230
MSCO
Overweight
Constellation Brands' FY20 guidance looks conservative, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian said he was surprised by the magnitude of the "relief rally" in Constellation Brands (STZ) shares following the company's Q4 report given that the company reported greater than expected near-term EPS dilution from its low-end wine sale, realized a lower than expected multiple on the wine transaction and unexpectedly did not provide forward guidance for Canopy Growth (CGC) equity losses. With that said, he sees "two clear positives" emerging from the quarter: the fact that fundamentals in the beer business remain solid and the fact that he sees solid visibility that Constellation can hit the high end of if $8.50-$8.80 FY20 EPS guidance, leaving aside Canopy equity losses. The analyst lowered his FY20 and FY21 EPS estimates to reflect dilution from the wine asset sale and trimmed his price target to $230 from $233, but he keeps an Overweight rating on Constellation shares.

TODAY'S FREE FLY STORIES

AXNX

Axonics

$25.49

0.53 (2.12%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Hot Stocks
Axonics announces FDA approval of Axonics r-SNM System »

Axonics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

EPAM

Epam Systems

$200.74

0.85 (0.43%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FENG

Phoenix New Media

$3.04

0.04 (1.33%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Phoenix New Media declares 17.14c per share special cash dividend »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.37

0.04 (3.01%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Athersys: Healios receives orphan designation for ARDS clinical program »

Athersys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:06
11/14/19
11/14
06:06
11/14/19
06:06
Recommendations
Cisco analyst commentary  »

Piper stays on sidelines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

GRUB

GrubHub

$36.63

-0.7 (-1.88%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Periodicals
GrubHub to create 'task force' after NYC Council threatens action, NYP says »

GrubHub will create a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTT

Wireless Telecom Group Inc

$1.50

0.04 (2.74%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Hot Stocks
Wireless Telecom Group Inc to Acquire Holzworth Instrumentation »

Wireless Telecom Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FVRR

Fiverr

$22.55

0.99 (4.59%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Fiverr rating change  »

Fiverr upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

ROLL

RBC Bearings

$165.06

-1.19 (-0.72%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Downgrade
RBC Bearings rating change  »

RBC Bearings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$155.38

-2.295 (-1.46%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

NRZ

New Residential

$16.06

-0.07 (-0.43%)

06:03
11/14/19
11/14
06:03
11/14/19
06:03
Downgrade
New Residential rating change  »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$2.50

0.04 (1.63%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Earnings
New Age Beverages reports Q3 EPS (14c), consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Periodicals
SoftBank's Yahoo Japan in talks to merge with Naver's Line, Nikkei reports »

SoftBank's Yahoo…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:01
11/14/19
11/14
06:01
11/14/19
06:01
Recommendations
Cisco analyst commentary  »

Citi keeps Buy on Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XRX

Xerox

$37.60

0.14 (0.37%)

, HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

06:00
11/14/19
11/14
06:00
11/14/19
06:00
Periodicals
Carl Icahn pushes for Xerox, HP Inc union, WSJ reports »

Carl Icahn, who owns a…

XRX

Xerox

$37.60

0.14 (0.37%)

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

MYO

Myomo

$0.54

-0.1126 (-17.26%)

05:58
11/14/19
11/14
05:58
11/14/19
05:58
Downgrade
Myomo rating change  »

Roth Capital downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

05:57
11/14/19
11/14
05:57
11/14/19
05:57
Syndicate
Fulgent Genetics 2.325M share Spot Secondary priced at $11.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ECOR

electroCore

$1.88

0.06 (3.30%)

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

electroCore

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:55
11/14/19
11/14
05:55
11/14/19
05:55
Conference/Events
SunTrust hosted company meetings at conference »

SunTrust hosted Meetings…

NICE

Nice

$159.16

0.87 (0.55%)

05:54
11/14/19
11/14
05:54
11/14/19
05:54
Earnings
Nice raises FY19 EPS view to $5.15-$5.35 from $5.13-$5.33, consensus $5.26 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

EMR

Emerson

$73.10

-0.47 (-0.64%)

05:52
11/14/19
11/14
05:52
11/14/19
05:52
Downgrade
Emerson rating change  »

HSBC downgrades Emerson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

NICE

Nice

$159.16

0.87 (0.55%)

05:51
11/14/19
11/14
05:51
11/14/19
05:51
Earnings
Nice reports Q3 EPS $1.30, consensus $1.28 »

Reports Q3 revenue $386M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

MIME

Mimecast

$43.42

0.28 (0.65%)

05:50
11/14/19
11/14
05:50
11/14/19
05:50
Hot Stocks
Mimecast acquires DMARC Analyzer »

Mimecast announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PRGS

Progress Software

$41.49

-0.36 (-0.86%)

05:48
11/14/19
11/14
05:48
11/14/19
05:48
Hot Stocks
Progress Software appoints Katie Kulikoski as Chief People Officer »

Progress announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.